EMED Electromedical Technologies, Inc
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1715819 · Fiscal year ends 12/31
Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-35.1%
TTM net income YoY46.3%
TTM EPS YoY—
Revenue 3-yr CAGR2.7%
Net income 3-yr CAGR—
Margins
Gross margin75.1%
Operating margin-109.6%
Net margin-182.0%
FCF margin—
EBITDA margin-109.6%
Returns
ROE—
ROA-236.0%
ROIC (approx.)—
Asset turnover1.30x
Leverage & solvency
Liabilities / assets804.1%
Debt / equity—
Current ratio0.07x
Interest coverage-4.38x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-217.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 | FY20192019-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.35M | $1.15M | $907,362 | $737,958 | $829,737 |
| Cost of revenue | $303,303 | $261,203 | $199,234 | $194,384 | $238,516 |
| Gross profit | $1.05M | $888,641 | $708,128 | $543,574 | $591,221 |
| R&D expense | $231,434 | $92,299 | $215,320 | $31,600 | $82,849 |
| SG&A expense | $3.11M | $2.49M | $4.51M | $3.71M | $2.26M |
| Operating income | -$2.06M | -$1.60M | -$3.80M | -$3.17M | -$1.67M |
| Interest expense | $893,155 | $791,072 | $3.31M | $769,591 | $54,814 |
| Net income | -$2.64M | -$3.47M | -$8.48M | -$3.87M | -$1.74M |
| EBITDA | -$2.06M | -$1.58M | -$3.78M | -$3.14M | -$1.64M |
| EPS (basic) | 0.00 | -0.03 | -0.24 | -0.20 | -0.10 |
| EPS (diluted) | 0.00 | -0.03 | -0.24 | -0.20 | -0.10 |
| Weighted avg. shares (diluted) | 377.22M | 133.60M | 50.99M | 22.30M | 16.81M |
| Balance sheet | |||||
| Cash & equivalents | $87,704 | $368,425 | $383,170 | $264,913 | $0 |
| Receivables | $4,399 | $9,444 | $35,085 | $17,694 | $15,667 |
| Inventory | $68,517 | $62,061 | $218,510 | $78,712 | $24,694 |
| Current assets | $449,185 | $647,802 | $674,767 | $647,179 | $106,192 |
| PP&E, net | $149,705 | $705,469 | $727,344 | $749,219 | $771,094 |
| Total assets | $748,383 | $1.35M | $1.40M | $1.42M | $902,866 |
| Current liabilities | $3.36M | $2.92M | $1.44M | $2.02M | $2.30M |
| Long-term debt | $150,000 | $671,525 | $702,780 | $732,266 | — |
| Total debt | $150,000 | $671,525 | $702,780 | $732,266 | — |
| Total liabilities | $3.62M | $3.57M | $2.12M | $2.74M | $3.09M |
| Shareholders' equity | -$2.87M | -$2.22M | -$722,503 | -$1.32M | -$2.18M |
| Net debt | $62,296 | $303,100 | $319,610 | $467,353 | — |
| Shares outstanding | 463.29M | 189.78M | 87.73M | 27.18M | 17.90M |
| Cash flow statement | |||||
| Operating cash flow | -$1.42M | -$773,337 | -$1.19M | -$1.34M | -$280,772 |
| Capital expenditure | $149,705 | — | — | — | — |
| Free cash flow | -$1.57M | — | — | — | — |
| Investing cash flow | $1.74M | — | — | — | — |
| Financing cash flow | -$608,211 | $758,592 | $1.31M | $1.60M | $280,772 |
| Depreciation & amortization | $4,557 | $21,875 | $21,875 | $21,875 | $24,457 |
| Stock-based compensation | $715,000 | $509,603 | $2.63M | $2.22M | $801,287 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.